Akamai Leaves Analysts Concerned Following Aggressive Shift To Computing, A Field Dominated By AWS, Azure, GCP

RBC Capital analyst Rishi Jaluria downgraded Akamai Technologies Inc (NASDAQ:AKAM) from Outperform to Sector Perform and reduced the price target from $100…
  • RBC Capital analyst Rishi Jaluria downgraded Akamai Technologies Inc (NASDAQ:AKAM) from Outperform to Sector Perform and reduced the price target from $100 to $85.
  • The re-rating reflected the shift from Security mix-shift to Compute mix-shift as Security growth slowed.
  • The analyst already had some skepticism post the Linode acquisition. 
  • Still, now Akamai seems to be going all-in on Compute, significantly growing its CapEx (21% of CY23E revenue) and re-allocating ~1,000 employees (10% of the headcount) to Compute.
  • It seems as if Akamai is trying to compete directly with the big hyperscalers Amazon.Com Inc (NASDAQ:AMZN) AWS, Microsoft Corp (NASDAQ:MSFT) Azure, Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL) Google Cloud Platform mostly on price, which is a challenging value proposition considering their deep moat.
  • Akamai would no longer be a significant cash generator with this seemingly all-in move.
  • Needham analyst Alex Henderson also reiterated a Hold on similar grounds.
  • Price Action: AKAM shares traded lower by 9.69% at $79.28 on the last check Wednesday.
Total
0
Shares
Related Posts
Read More

Zoom Q1 Earnings: Revenue Beat, EPS Beat, Cash Flow Surges, Continued AI Integration And More

Zoom reports first-quarter revenue of $1.14 billion, beating the consensus estimate of $1.13 billion billion. Zoom's top-line results were up 3.2% on a year-over-year basis. Enterprise revenue was up 5.3% year-over-year, while online revenue was flat on a year-over-year basis. The communications company reported adjusted earnings of $1.35 per share, beating analyst estimates of $1.20 per share.

ZM

Read More

Marijuana Giant Trulieve Boosts Cash Position With $25M Loan, Opens Cannabis Stores In Florida

Florida-based medical cannabis firm Trulieve Cannabis has secured $25m of gross proceeds from a five-year loan. The company will pay interest of 8.31% until the loan matures. The deal, arranged with First Federal bank, gives Trulieve greater flexibility, according to CEO Kim Rivers. She said the loan would boost the company's cash position as it gears up for growth opportunities. The company revealed the financing at the same time as the opening of two new medical dispensaries in Florida: one in Crawfordville and another in Crestview. Trulieve will stock products from in-house brands Modern Flower, Muse, Trekkers and many others. The dispensaries will also carry product from partner brands, including Alien Labs.

CSE:TRUL